AVISE Vasculitis AAV

The complete panel of ANCA-associated markers for a swift and accurate assessment of your patient’s disease state.

It is an advanced diagnostic test specifically designed to aid in the differential diagnosis of AAV. AVISE Vasculitis AAV exemplifies the rigorous quality that is at the core of all AVISE testing products.

Rapid and accurate testing is essential to prevent death and long-term disability from AAV

Signs and symptoms of ANCA-associated vasculitis (AAV) vary greatly and are not always indicative of the severity of the disease state.

ANNUAL INCIDENCE
20
per million1
MORTALITY
25%
at five years2
Image

Rapid and accurate testing is essential to prevent death and long-term disability from AAV

Signs and symptoms of ANCA-associated vasculitis (AAV) vary greatly and are not always indicative of the severity of the disease state.

ANNUAL INCIDENCE
20
per million1
MORTALITY
25%

at five years2

Image

AVISE Vasculitis AAV

It is composed from the following markers:

AVISE Vasculitis Test Report

Image
Download Report

References

 

  1. Draibe JB, Fulladosa X, Cruzado JM, et al. Current and novel biomarkers in anti-neutrophil cytoplasm-associated vasculitis. Clin Kidney J. 2016;9(4):547-551. doi:10.1093/ckj/sfw056
  2. Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S94-S104.1 
  3. Damoiseaux J, Csernok E, Rasmussen N, et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): A multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunoˆuorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis. 2017;76(4):647-653. doi:10.1136/annrheumdis-2016-209507
  4. Savige J, Gillis D, Benson E, et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol. 1999;111(4):507-13. doi: 10.1093/ajcp/111.4.507
  5. Bossuyt X, Tervaert JW, Arimura Y, et al. Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheum. 2017;13:683-692. doi: 10.1038/nrrheum.2017.140
  6. Wallace ZS, Miloslavsky EM. Management of ANCA associated vasculitis. BMJ. 2020;368(March):1-16. doi:10.1136/bmj.m421
  7. Mahler M, Radice A, Yang W, et al. Clinica Chimica Acta Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. Clin Chim Acta. 2012;413(7-8):719-726. doi:10.1016/j.cca.2012.01.004
  8. Mahler M, Radice A, Sinico RA, et al. Performance evaluation of a novel chemiluminescence assay for detection of anti-GBM antibodies: an international multicenter study. Nephrolog Dial Transplant. 2012;27(1):243-52. doi:10.1093/ndt/gfr203